Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.

Viruses - 3 Jun 2026

Jia Tianrong, Huang Zehong, Xia Ningshao, Yuan Quan

Abstract excerpt

The high-frequency mutation characteristics of SARS-CoV-2 have posed formidable challenges to the development of vaccines and therapeutic agents. Neutralizing antibodies, which serve as effective tools for prevention and control, have undergone continuous updates and iterations in response to viral mutations. This article provides a comprehensive review of researchers' efforts to achieve both high neutralizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitopes

Share to Protein Engineering

Share to SARS-CoV-2

Share to Single-Domain Antibodies

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 42357652
DOI: 10.3390/v18060642
PMCID: PMC13308482

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.PMID 42357652Read ↗

Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silicoSemantic proximity Read ↗

Broadening a SARS-CoV-1–neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolutionSemantic proximity Read ↗

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2Semantic proximity Read ↗

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2Semantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

Neutralizing antibodies targeting SARS-CoV-2 spike proteinSemantic proximity Read ↗

A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variantsSemantic proximity Read ↗

Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster modelsSemantic proximity Read ↗

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2Semantic proximity Read ↗

Broad Neutralization Activity of SARS-CoV-2 Antibody is Achieved by Coordinated Recognition of Virus Vulnerable SiteSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.